Keith Berelowitz, Richmond Pharmacology’s Director of Operations, wrote recently for Pharmaceutical Market Europe where he outlined methods that facilitate the successful recruitment and retention of patients - an essential element to delivering clinical studies on time.

The article focuses on the growing emphasis on improved patient engagement in trial development.  A key element in the success of clinical trials lies in the availability and subsequent experience of people volunteering to participate. It is therefore crucial that Richmond Pharmacology and trial sponsors understand patients’ lives and the factors that drive a patient’s decision to take part in a study. Examples are shared in the article about effective ways of doing this.

Richmond Pharmacology understands the importance of having a good relationship with patient volunteers. This can be achieved by removing potential barriers to trial participation, as well as ensuring that the volunteer is treated as an individual, rather than given a one-size-fits-all experience. Keith also highlights other criteria that sponsors should look for in a Contract Research Organisation (CRO) regarding patient retention – for example a guarantee that a trial will take place in a single centre research facility and that interaction with patients is never outsourced to a third party.

To read the full article, click here

Latest news

Richmond Pharmacology Announces Promotion of Dr Priscilla Ochuba to Associate Medical Director

August 1, 2025
Richmond Pharmacology is pleased to announce the promotion of Dr Priscilla Ochuba to Associate Medical Director, effective 1st August 2025.
Read more

Red4Research Blog – Alan’s Story

June 24, 2025
#Red4Research is a global initiative that recognises the essential role of clinical research in improving treatment, outcomes, and the future of medicine.
Read more

Events

JSCPT 2025

5th –6th December 2025
Richmond Pharmacology will attend JSCPT 2025 in Tokyo, represented by their leadership team. Topics include early-phase studies, bridging studies between Europe and Asia, gene and RNA-based therapy development, and cross-border collaboration.
View event